WHO ICTRP trial
Efficacy and Safety of Daratumumab in the Treatment of Lupus Nephritis: A…
ChiCTR2500106706 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500106706 |
|---|---|
| Public title | Efficacy and Safety of Daratumumab in the Treatment of Lupus Nephritis: A Multicenter, Prospective Study |
| Scientific title | Efficacy and Safety of Daratumumab in the Treatment of Lupus Nephritis: A Multicenter, Prospective Study |
| Primary sponsor | The First Affiliated Hospital of Fujian Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | lupus nephritis |
| Interventions | Intervention Group:In addition to conventional therapy, daratumumab 800 mg will be administered every two weeks for a total of four doses;Control group:Standard therapy plus belimumab 10 mg/kg on Days 0, 14, and 28, then every 4 weeks for… |
| Registration date | Jul 29, 2025 |
| Target size | Intervention Group:20;Control group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: